http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 30 Jul 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html <p align="justify">TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2d0bsYDLZz7HYNao5ChapBYmwo0S6jYX6LzOAcZN8GX0hW73CFIGmP3yZmOkZK2qOFI70NMhD7wv_0TZqBNQIw==" http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html Thu, 30 Jul 2026 07:30:00 -0400 MDMA MDXXF O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html <p align="justify">TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2d0bsYDLZz7HYNao5ChapBYmwo0S6jYX6LzOAcZN8GX0hW73CFIGmP3yZmOkZK2qOFI70NMhD7wv_0TZqBNQIw==" http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html Thu, 30 Jul 2026 07:30:00 -0400 MDMA MDXXF O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html <p align="justify">TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2d0bsYDLZz7HYNao5ChapBYmwo0S6jYX6LzOAcZN8GX0hW73CFIGmP3yZmOkZK2qOFI70NMhD7wv_0TZqBNQIw==" http://www.streetinsider.com/Press+Releases/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html Thu, 30 Jul 2026 07:30:00 -0400 MDMA MDXXF O.56213031 http://www.streetinsider.com/Globe+Newswire/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html <p align="justify">TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2d0bsYDLZz7HYNao5ChapBYmwo0S6jYX6LzOAcZN8GX0hW73CFIGmP3yZmOkZK2qOFI70NMhD7wv_0TZqBNQIw==" http://www.streetinsider.com/Globe+Newswire/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html Thu, 30 Jul 2026 07:30:00 -0400 MDMA MDXXF O.56213031 http://www.streetinsider.com/Globe+Newswire/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html <p align="justify">TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2d0bsYDLZz7HYNao5ChapBYmwo0S6jYX6LzOAcZN8GX0hW73CFIGmP3yZmOkZK2qOFI70NMhD7wv_0TZqBNQIw==" http://www.streetinsider.com/Globe+Newswire/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html Thu, 30 Jul 2026 07:30:00 -0400 MDMA MDXXF O.56213031 http://www.streetinsider.com/Globe+Newswire/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html <p align="justify">TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2d0bsYDLZz7HYNao5ChapBYmwo0S6jYX6LzOAcZN8GX0hW73CFIGmP3yZmOkZK2qOFI70NMhD7wv_0TZqBNQIw==" http://www.streetinsider.com/Globe+Newswire/PharmAla+Issues+Q3+Financial+Statements+and+AGM+Update/26838836.html Thu, 30 Jul 2026 07:30:00 -0400 MDMA MDXXF O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Press+Releases/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html <p align="justify">TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- <strong>PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF)</strong>, a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.</p> <p align="justify">With drug substance manufacturing now complete, the Company is prepared to begin GMP manufacturing of the drug product, the formulated finished form http://www.streetinsider.com/Globe+Newswire/PharmAla+Completes+GMP+Manufacturing+of+Drug+Substance+components+for+ALA-002+Provides+Corporate+Update+Regarding+ALA-002+Asset/26733099.html Mon, 06 Jul 2026 08:15:00 -0400 A.31828608 MDMA MDXXF O.56213031 O.60475740 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031 http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“<strong>PharmAla</strong>” or the “<strong>Company</strong>”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered into a term sheet (the “<strong>Term Sheet</strong>”) under which PharmAla would grant Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“<strong>Jupiter</strong>”) exclusive, perpetual United States licensing rights to ALA-002, PharmAla’s lead drug candidate and a next-generation, non-racemic MDMA Novel Chemical Entity. The total potential value of the proposed transaction is in excess of US$100 million through a combination of upfront consideration, development http://www.streetinsider.com/Press+Releases/PharmAla+Biotech+Signs+Term+Sheet+to+License+Exclusive+U.S.+Rights+to+ALA-002%2C+Its+Next-Generation+MDMA+Therapeutic%2C+to+Jupiter+Neurosciences%2C+Inc.+%28NASDAQ%3A+JUNS%29+in+a+Transaction+Valued+at+Over+%24100+/26525255.html Wed, 20 May 2026 08:15:00 -0400 A.06822034 A.09231922 A.25842716 JUNS MDMA MDXXF O.20026344 O.20317911 O.51065074 O.52729045 O.56213031